Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients

HIV Medicine

Volumn 2, Issue 1, 2001, Pages 35-42

  Battegay, M ^a   Vernazza, Pl ^b   Bernasconi, E ^c   Flepp, M ^d   Sendi, P ^a   Erb, P ^e   Malinverni, R ^f   Jaccard, C ^g   Morgenthaler, S ^h   Bedoucha, V ^h   Hirschel, B ⁱ  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c Department of Obstetrics and Gynecology   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

HIV DNA; Protease inhibitor; Ritonavir; Saquinavir

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; ASTHENIA; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG CAPSULE; FATIGUE; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; PANCREAS CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; STAVUDINE; SWITZERLAND; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035198562     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00047.x     Document Type: Article

References (26)

1. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
4. Safety and activity of saquinavir in HIV infection
5. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV disease
6. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
7. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
8. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study
9. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
10. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
11. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy
12. Durability of quadruple antiretroviral therapy including ritonavir and saquinavir in patients with advanced HIV-1 disease
13. Efficacy of a four drug combination therapy including two protease inhibitors in patients with advanced HIV-1 illness
14. The antiviral effect of ritonavir and saquinavir among HIV infected adults: Preliminary results from a community based study
15. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
16. Virologic responses to a ritonavir - Saquinavir-containing regimen in patients who had previously failed nelfinavir
17. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
18. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
19. Optimization of quantitative culture assay for human immunodeficiency virus from plasma
20. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates
21. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
22. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
23. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
24. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals
25. HIV phenotype switching during antiretroviral therapy: Emergence of saquinavir-resistant strains with less cytopathogenicity
26. 6/1 CD4 cells treated with highly active antiretroviral therapy